Simvastatin inhibits CD44 fragmentation in chondrocytes

Area of Science:

• Cell Biology
• Biochemistry
• Rheumatology

Background:

• Hyaluronan receptor CD44 is proteolytically cleaved in osteoarthritic chondrocytes, a process linked to cholesterol-rich lipid rafts.
• This cleavage may contribute to the pathology of osteoarthritis.

Purpose of the Study:

• To investigate the protective effects of statins on articular chondrocytes by examining their impact on cellular cholesterol levels.
• To determine if simvastatin can prevent CD44 cleavage and preserve chondrocyte function.

Main Methods:

• Utilized three chondrocyte models: human HCS-2/8 chondrosarcoma cells, human osteoarthritic chondrocytes, and normal bovine articular chondrocytes.
• Induced CD44 fragmentation using IL-1β + Oncostatin M, then assessed the effects of simvastatin pre-treatment.
• Investigated CD44 fragmentation, lipid raft transit, ADAM10 activity, CD44-ADAM10 interaction, and pericellular matrix retention.

Main Results:

• IL-1β + Oncostatin M significantly increased CD44 fragmentation in all chondrocyte models.
• Simvastatin pre-treatment decreased CD44 fragmentation, reduced CD44's lipid raft transit, lowered ADAM10 activity, and diminished CD44-ADAM10 interaction.
• ADAM10 knockdown blocked CD44 fragmentation; simvastatin's protective effects were reversed by cholesterol and farnesyl-pyrophosphate addition.

Conclusions:

• Simvastatin exerts protective effects on articular chondrocytes by reducing CD44 fragmentation, likely through cholesterol level modulation.
• This mechanism preserves pericellular matrix integrity, suggesting a potential therapeutic role for statins in osteoarthritis.
• Targeting cholesterol metabolism may offer a novel strategy for managing chondrocyte dysfunction in osteoarthritis.